Vanguard Group Inc. Has $31.29 Million Stock Holdings in Enfusion, Inc. (NYSE:ENFN)

Vanguard Group Inc. increased its holdings in shares of Enfusion, Inc. (NYSE:ENFN) by 17.2% in the 3rd quarter, HoldingsChannel reports. The firm owned 3,487,815 shares of the company’s stock after acquiring an additional 512,479 shares during the period. Vanguard Group Inc.’s holdings in Enfusion were worth $31,286,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in ENFN. Hudson Bay Capital Management LP increased its stake in Enfusion by 29.7% in the third quarter. Hudson Bay Capital Management LP now owns 460,084 shares of the company’s stock valued at $4,127,000 after purchasing an additional 105,236 shares in the last quarter. Algert Global LLC bought a new stake in Enfusion in the 3rd quarter valued at about $139,000. New York State Common Retirement Fund increased its position in Enfusion by 17.2% in the 3rd quarter. New York State Common Retirement Fund now owns 1,618,803 shares of the company’s stock valued at $14,521,000 after buying an additional 237,841 shares in the last quarter. Swiss National Bank raised its stake in Enfusion by 55.7% during the 3rd quarter. Swiss National Bank now owns 49,500 shares of the company’s stock worth $444,000 after buying an additional 17,700 shares during the period. Finally, Amalgamated Bank boosted its holdings in Enfusion by 33.7% in the third quarter. Amalgamated Bank now owns 5,230 shares of the company’s stock worth $47,000 after acquiring an additional 1,317 shares in the last quarter. 81.05% of the stock is currently owned by institutional investors.

Enfusion Trading Down 0.3 %

Shares of Enfusion stock opened at $9.53 on Friday. The company has a market capitalization of $1.22 billion, a P/E ratio of 119.14, a price-to-earnings-growth ratio of 2.80 and a beta of 1.00. The stock has a fifty day simple moving average of $8.95 and a 200 day simple moving average of $9.10. Enfusion, Inc. has a 12-month low of $7.37 and a 12-month high of $11.56.

Enfusion (NYSE:ENFN) last posted its quarterly earnings data on Tuesday, March 12th. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The firm had revenue of $46.49 million for the quarter, compared to analysts’ expectations of $45.56 million. Enfusion had a return on equity of 10.30% and a net margin of 3.45%. On average, analysts predict that Enfusion, Inc. will post 0.07 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ENFN shares. Piper Sandler boosted their price objective on Enfusion from $9.00 to $10.00 and gave the company a “neutral” rating in a report on Wednesday, December 20th. Bank of America lifted their price target on shares of Enfusion from $8.00 to $9.00 and gave the company an “underperform” rating in a research report on Wednesday, March 13th. The Goldman Sachs Group downgraded shares of Enfusion from a “neutral” rating to a “sell” rating and lowered their price objective for the stock from $9.00 to $8.00 in a report on Wednesday, February 28th. Finally, JPMorgan Chase & Co. cut shares of Enfusion from a “neutral” rating to an “underweight” rating and reduced their price objective for the company from $11.00 to $9.00 in a report on Tuesday, January 30th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $9.33.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.